

PD-L1 Monoclonal Antibody(Capture)

catalog number: AN001380P

Note: Centrifuge before opening to ensure complete recovery of vial contents.

Description


Reactivity	Human
Immunogen	Recombinant Human PD-L1 L1 protein expressed by Mammalian
Host	Mouse
Isotype	Mouse IgG1
Clone	9B7
Purification	Protein A/G Purification
Conjugation	Unconjugated
Buffer	Phosphate buffered solution, pH 7.2, containing 0.05% proclin 300.

Applications

Recommended Dilution

ELISA Capture	2-8 µg/mL
----------------------	-----------

Data



Sandwich ELISA-Recombinant Human PD-L1 L1 protein standard curve. Background subtracted standard curve using PD-L1 antibody(AN001380P)(Capture), PD-L1 antibody(AN001390P)(Detector) in sandwich ELISA. The reference range value for Recombinant Human PD-L1 L1 protein is 0.16-10 ng/mL.

Preparation & Storage

Storage	Store at 4°C valid for 12 months or -20°C valid for long term storage, avoid freeze / thaw cycles.
Shipping	The product is shipped with ice pack, upon receipt, store it immediately at the temperature recommended.

Background

Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10). Can also act as a transcription coactivator: in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival. The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function. The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy.

For Research Use Only